Diabetes and Obesity Drug Makers Struggle to Keep Up with Exploding Demand

Novo Nordisk and Eli Lilly see huge demand and sales for their new diabetes and obesity drugs like Wegovy, Ozempic, and Mounjaro.

The companies are struggling to manufacture enough supply to meet the rapidly growing demand. This could worsen when Mounjaro is approved for obesity.

Novo is now Europe's most valuable company, while Lilly is the world's most valuable healthcare firm, thanks to these blockbuster drugs.

The drugs' success is hurting medical device companies and food/beverage firms as obesity declines.

Analysts say tight supply of the drugs limits sales for now, but growth could accelerate once capacity expands.